Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial (2019) Jarczyk J, Wirtz R, Roghmann F, Juette H, Kriegmair MC, Worst TS, Sikic D, et al. Conference contribution Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting (2019) Roghmann F, Wirtz R, Jarczyk J, Kriegmair MC, Worst TS, Sikic D, Wach S, et al. Conference contribution Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019) Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al. Conference contribution Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency results based on multiple RNA extraction kits and mutation detection methods (2019) Weyerer V, Stöhr R, Juette H, Wirtz R, Eckstein M, Roghmann F, Breyer J, et al. Conference contribution Comparative analysis of tumour mutational burden (TMB) prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer (UBC) (2019) Eckstein M, Hartmann A, Strissel P, Strick R, Wach S, Taubert H, Wullich B, et al. Conference contribution A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12 (2019) Hofheinz R, Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al. Conference contribution Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019) Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al. Conference contribution Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial (2019) Fasching P, Quek RGW, Bhattacharyya H, Hurvitz SA, Rugo HS, Ettl J Conference contribution Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy (2019) Huang M, Qi CZ, Ramsey S, Briggs A, Zhao J, Haiderali A, Karantza V, et al. Conference contribution